Effects of gabapentin on the motor response to levodopa: A double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease

Clinical Neuropharmacology

Volumn 27, Issue 3, 2004, Pages 124-128

  Van Blercom, N ^a   Lasa, A ^c   Verger, K ^b   Masramon X ^b   Sastre, V M ^b   Linazasoro, Gurutz ^a  

^a HOSPITAL QUIRÓN   (Spain)

^b Euroclin Institute   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; LEVODOPA; PLACEBO;

4 AMINOBUTYRIC ACID RELEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; FALLING; GABAERGIC SYSTEM; GAIT DISORDER; GLOBUS PALLIDUS; HUMAN; LATENT PERIOD; LUNG EMBOLISM; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; URINE RETENTION;

ACETIC ACIDS; AGED; AMINES; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; GAMMA-AMINOBUTYRIC ACID; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; REACTION TIME; TIME FACTORS;

EID: 2942556503     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200405000-00007     Document Type: Article

References (25)

1. Obeso JA, Linazasoro G, Gorospe A, et al. Complications associated with chronic levodopa therapy in Parkinsońs disease. In Olanow CW, Obeso JA, eds. Beyond the decade of the brain vol 2 Kent: Wells Medical Ltd 1997:11-36.
2. Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia. Ann Neurol. 2000;47(suppl 1):105-114.
3. Parent A, Hazrati LN. Functional anatomy of the basal ganglia I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 1995;20:91-127.
4. Lees AJ, Shaw KM, Stem GM. Baclofen in Parkinsońs disease. J Neurol Neurosurg Psychiatry. 1978;41:707-708.
5. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46:409-427.
6. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Matson RH, Meldrum BS, eds. Antiepileptic drugs. New York, NY: Raven Press, 1995:829-841.
7. Reeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia. 1996;37:988-990.
8. Buetefisch CM, Gutiérrez A, Gutmann L. Choreoathetotic movements: A posible side effect of gabapentin. Neurology. 1996;46:851-852.
9. Palomeras E, Sanz P, Cano A, et al. Dystonia in a patient treated with propranolol and gabapentin. Arch Neurol. 2000;57:570-571.
10. Olson WL, Gruenthal M, Mueller ME, et al. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med. 1997; 102:60-66.
11. Chaná P, de Marinis A, Barrientos N. Gabapentin and motor fluctuations in Parkinsońs disease. Mov Disord. 1997;12:608.
12. Langston JW, Winder H, Goetz CG, et al. Core assessment program for intracerebral transplantation (CAPIT). Mov Disord. 1992;7:2-13.
13. Marsden CD, Sheehy MP. GABA and movement disorders. Adv Biochem Psychopharmacol. 1981;30:225-234.
14. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAa receptors in the striatopallidal complex. Brain Res. 1995;680:43-52.
15. Calon F, Morissette M, Goulet M, et al. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA (A)/benzodiazepine receptor complex and GABA content. Neurochem Int. 1999;35:81-91.
16. Calon F, Di Paolo T. Levodopa response motor complications: GABA receptors and preproenkephalin expression in human brain. Parkinsonism and related disorders. 2002;8:449-454.
17. Calon F, Morisette M, Rajput AH, et al. Changes in GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord. 2003;18:241-253.
18. Lozano AM, Carella F. Physiologic studies in the human brain in movement disorders. Parkinsonism and related disorders. 2002;8:455-458.
19. Turjanski N, Lees AJ. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry. 1992;55:413.
20. Ziegler M, Fournier V, Bathien N, et al. Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias. Clin Neuropharmacol. 1987;10:238-246.
21. Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry. 1978;41:702-706.
22. Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinsońs disease. Mov Disord. 2003;18:683-711.
23. Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56:475-480.
24. Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord. 1998;13:465-467.
25. Ondo W, Hunter C, Vuong KD, et al. Gabapentin for esential tremor: a multiple-dose, double blind, placebo controlled trial. Mov Disord. 2000; 15:678-682.